Abstract
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, accounting for 80 % of thyroid carcinomas in adults and 90 % in children. PTC is a malignant epithelial tumor showing follicular differentiation and distinctive nuclear features. Patients usually are 20–50 years old, but those of any age may be affected. PTC is more common in women than men. Most PTCs are sporadic but may occur with syndromes such as Gardner syndrome, Cowden syndrome, and ataxia telangiectasia. PTC may arise in ectopic thyroid tissue such as struma ovarii, adrenal glands, and trachea. Radiation exposure is a risk factor for PTC. Histologic variants of PTC are important to recognize prognostically and for association with other diseases. Aggressive variants include tall cell, columnar cell, solid, and the recently described hobnail variant. The cribriform-morular variant often is associated with familial adenomatous polyposis. PTCs are positive for thyroglobulin, thyroid transcription factor 1 (TTF1), and keratins and are negative for calcitonin, chromogranin, and synaptophysin. Markers useful in confirming a diagnosis of PTC are HBME-1, keratin 19, galectin-3, and CITED1. BRAF mutations occur in about 60 % of PTCs, and RET/PTC rearrangements occur in 20–30 % of adult PTCs. BRAF mutation and RET/PTC rearrangement are mutually exclusive abnormalities in PTCs. RET/PTC1 is more common in papillary microcarcinomas and PTCs with classic architectural features, whereas RET/PTC3 is more common in the solid variant. BRAF mutations occur in classic, Warthin-like, and oncocytic PTCs; microcarcinomas; and aggressive variants such as tall cell, columnar, and hobnail PTCs. Poorly differentiated and anaplastic thyroid carcinomas also may show BRAF mutation, particularly if associated with or dedifferentiated from a PTC. BRAF mutation is not common in pediatric or radiation-associated PTCs. The follicular variant of PTC (FVPTC) is associated with RAS mutations (as are follicular neoplasms), thus RAS is not useful in separating FVPTC from follicular neoplasms. PTCs usually metastasize to cervical nodes, particularly ipsilateral nodes, before spreading to the lung and other sites. Unfavorable prognostic features are older age, male sex, large tumor size, multicentricity, angiolymphatic invasion, necrosis, mitoses, extrathyroid extension, distant metastases, high grade, marked nuclear atypia, and progression to poorly or undifferentiated carcinoma. PTCs are treated by thyroidectomy and removal of involved lymph nodes. Radioactive iodine may be used to ablate any remaining tumor, including metastatic sites. Overall, PTC has an excellent prognosis, with >90 % survival, and most patients survive even with metastatic disease.
Access provided by Autonomous University of Puebla. Download chapter PDF
Keywords
- Papillary Thyroid Carcinoma
- Familial Adenomatous Polyposis
- BRAF Mutation
- Ataxia Telangiectasia
- Anaplastic Thyroid Carcinoma
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, accounting for 80 % of thyroid carcinomas in adults and 90 % in children [1]. PTC is a malignant epithelial tumor showing follicular differentiation and distinctive nuclear features [2]. Patients usually are 20–50 years old, but those of any age may be affected [2]. PTC is more common in women than men. Most PTCs are sporadic but may occur with syndromes such as Gardner syndrome, Cowden syndrome, and ataxia telangiectasia [3, 4]. PTC may arise in ectopic thyroid tissue such as struma ovarii, adrenal glands, and trachea [5–7]. Radiation exposure is a risk factor for PTC [8]. Histologic variants of PTC are important to recognize prognostically and for association with other diseases. Aggressive variants include tall cell, columnar cell, solid, and the recently described hobnail variant. The cribriform-morular variant often is associated with familial adenomatous polyposis. PTCs are positive for thyroglobulin, thyroid transcription factor 1 (TTF1), and keratins and are negative for calcitonin, chromogranin, and synaptophysin. Markers useful in confirming a diagnosis of PTC are HBME-1, keratin 19, galectin-3, and CITED1. BRAF mutations occur in about 60 % of PTCs, and RET/PTC rearrangements occur in 20–30 % of adult PTCs. BRAF mutation and RET/PTC rearrangement are mutually exclusive abnormalities in PTCs. RET/PTC1 is more common in papillary microcarcinomas and PTCs with classic architectural features, whereas RET/PTC3 is more common in the solid variant. BRAF mutations occur in classic, Warthin-like, and oncocytic PTCs; microcarcinomas; and aggressive variants such as tall cell, columnar, and hobnail PTCs. Poorly differentiated and anaplastic thyroid carcinomas also may show BRAF mutation, particularly if associated with or dedifferentiated from a PTC. BRAF mutation is not common in pediatric or radiation-associated PTCs. The follicular variant of PTC (FVPTC) is associated with RAS mutations (as are follicular neoplasms), thus RAS is not useful in separating FVPTC from follicular neoplasms. PTCs usually metastasize to cervical nodes, particularly ipsilateral nodes, before spreading to the lung and other sites [1]. Unfavorable prognostic features are older age, male sex, large tumor size, multicentricity, angiolymphatic invasion, necrosis, mitoses, extrathyroid extension, distant metastases, high grade, marked nuclear atypia, and progression to poorly or undifferentiated carcinoma [1, 9]. PTCs are treated by thyroidectomy and removal of involved lymph nodes. Radioactive iodine may be used to ablate any remaining tumor, including metastatic sites. Overall, PTC has an excellent prognosis, with >90 % survival, and most patients survive even with metastatic disease.
Classic PTC
Papillary Thyroid Microcarcinoma
FVPTC
Cribriform-Morular Variant of PTC
Warthin-Like Variant of PTC
Diffuse Sclerosing Variant of PTC
Oxyphilic (Oncocytic/Hurthle Cell) Variant of PTC
Solid Variant of PTC
Tall Cell Variant of PTC
Columnar Variant of PTC
Hobnail Variant of PTC
References
Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland, Atlas of tumor pathology, vol. 5. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1992. p. 343.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs, World Health Organization classification of tumours. Lyon: IARC Press; 2004. p. 320.
Sandoval C, et al. Parotid and thyroid gland cancers in patients with ataxia-telangiectasia. Pediatr Hematol Oncol. 2001;18(8):485–90.
Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol. 2001;13(1):44–51.
Schmidt J, et al. BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol. 2007;31(9):1337–43.
Bohinc BN, et al. Micropapillary thyroid carcinoma and concomitant ectopic thyroid tissue in the adrenal gland: metastasis or metaplasia? Thyroid. 2011;21(9):1033–8.
Hari CK, Brown MJ, Thompson I. Tall cell variant of papillary carcinoma arising from ectopic thyroid tissue in the trachea. J Laryngol Otol. 1999;113(2):183–5.
Calandra DB, et al. Total thyroidectomy in irradiated patients. A twenty-year experience in 206 patients. Ann Surg. 1985;202(3):356–60.
Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–8.
Erickson LA, et al. p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol. 2000;13(9):1014–9.
Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006;13(2):69–75.
Neuhold N, Kaiser H, Kaserer K. Latent carcinoma of the thyroid in Austria: a systematic autopsy study. Endocr Pathol. 2001;12(1):23–31.
de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocr Pathol. 2006;17(2):165–73.
Sakorafas GH, et al. Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease. J Postgrad Med. 2007;53(1):23–6.
Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531–8.
Wada N, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.
Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46(1):209–16.
Lo CY, et al. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006;30(5):759–66.
Zhao Q, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2013;20(3):746–52.
Lissak B, et al. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest. 1995;18(10):813–6.
Lin KD, et al. Skull metastasis with brain invasion from thyroid papillary microcarcinoma. J Formos Med Assoc. 1997;96(4):280–2.
Lupoli G, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999;353(9153):637–9.
Haas SN. Management of papillary microcarcinoma of the thyroid. S D Med. 2006;59(10):425–7.
Orsenigo E, et al. Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol. 2004;30(10):1104–6.
Kuo EJ, et al. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph node metastases: a population-level analysis. Thyroid. 2013;23(10):1305–11.
Baloch ZW, LiVolsi VA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol. 2000;13(8):861–5.
Liu J, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107(6):1255–64.
Vivero M, Kraft S, Barletta JA. Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid. 2013;23(3):273–9.
Howitt BE, et al. Molecular alterations in partially-encapsulated/well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid. 2013;23(10):1256–62.
Lloyd RV, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28(10):1336–40.
Lang BH, et al. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg. 2006;30(5):752–8.
Lin HW, Bhattacharyya N. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope. 2010;120 Suppl 4:S163.
Yu XM, et al. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263–8.
Ivanova R, et al. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch. 2002;440(4):418–24.
Mizukami Y, et al. Diffuse follicular variant of papillary carcinoma of the thyroid. Histopathology. 1995;27(6):575–7.
Nakamura N, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006;17(3):213–23.
Chan JK, Loo KT. Cribriform variant of papillary thyroid carcinoma. Arch Pathol Lab Med. 1990;114(6):622–4.
Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25(6):549–61.
Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12(4):400–11.
Soravia C, et al. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol. 1999;154(1):127–35.
Xu B, et al. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol. 2003;199(1):58–67.
Hirokawa M, et al. Morules in cribriform-morular variant of papillary thyroid carcinoma: immunohistochemical characteristics and distinction from squamous metaplasia. APMIS. 2004;112(4–5):275–82.
Jung CK, et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid. 2009;19(8):905–13.
Apel RL, Asa SL, LiVolsi VA. Papillary Hurthle cell carcinoma with lymphocytic stroma. “Warthin-like tumor” of the thyroid. Am J Surg Pathol. 1995;19(7):810–4.
Vickery Jr AL, et al. Papillary carcinoma. Semin Diagn Pathol. 1985;2(2):90–100.
Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol. 1989;13(12):1041–9.
Lam AK, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol. 2006;13(2):176–81.
Gomez-Morales M, et al. Diffuse sclerosing papillary carcinoma of the thyroid gland: immunohistochemical analysis of the local host immune response. Histopathology. 1991;18(5):427–33.
Soares J, Limbert E, Sobrinho-Simoes M. Diffuse sclerosing variant of papillary thyroid carcinoma. A clinicopathologic study of 10 cases. Pathol Res Pract. 1989;185(2):200–6.
Thompson LD, Wieneke JA, Heffess CS. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol. 2005;16(4):331–48.
Chan JK, Tsui MS, Tse CH. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a histological and immunohistochemical study of three cases. Histopathology. 1987;11(2):191–201.
Herrera MF, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg. 1992;16(4):669–74; discussion 774–5.
Mai KT, et al. Pathologic study and clinical significance of Hurthle cell papillary thyroid carcinoma. Appl Immunohistochem Mol Morphol. 2004;12(4):329–37.
Besic N, et al. Aggressiveness of therapy and prognosis of patients with Hurthle cell papillary thyroid carcinoma. Thyroid. 2006;16(1):67–72.
Nikiforov YE, et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. 2001;25(12):1478–84.
Keelawat S, Poumsuk U. Association between different variants of papillary thyroid carcinoma and risk-group according to AMES (age, metastasis, extent and size) classification system. J Med Assoc Thai. 2006;89(4):484–9.
Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991–1992) from the Republic of Belarus. Cancer. 1994;74(2):748–66.
Nikiforova MN, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 2004;209(1):1–6.
Santoro M, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer. 2000;82(2):315–22.
Williams ED, et al. Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer. 2004;90(11):2219–24.
Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008;18(11):1179–81.
Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43(4):207–15.
Johnson TL, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12(1):22–7.
Hicks MJ, Batsakis JG. Tall cell carcinoma of the thyroid gland. Ann Otol Rhinol Laryngol. 1993;102(5):402–3.
Ghossein RA, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17(7):655–61.
Ferreiro JA, Hay ID, Lloyd RV. Columnar cell carcinoma of the thyroid: report of three additional cases. Hum Pathol. 1996;27(11):1156–60.
Evans HL. Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol. 1986;85(1):77–80.
Evans HL. Encapsulated columnar-cell neoplasms of the thyroid. A report of four cases suggesting a favorable prognosis. Am J Surg Pathol. 1996;20(10):1205–11.
Akslen LA, Varhaug JE. Thyroid carcinoma with mixed tall-cell and columnar-cell features. Am J Clin Pathol. 1990;94(4):442–5.
Putti TC, Bhuiya TA. Mixed columnar cell and tall cell variant of papillary carcinoma of thyroid: a case report and review of the literature. Pathology. 2000;32(4):286–9.
Wenig BM, et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;82(4):740–53.
Hirokawa M, et al. Columnar cell carcinoma of the thyroid: MIB-1 immunoreactivity as a prognostic factor. Endocr Pathol. 1998;9(1):31–4.
Chen JH, et al. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol. 2011;24(5):739–49.
Sujoy V, Pinto A, Nosé V. Columnar cell variant of papillary thyroid carcinoma: a study of ten cases with emphasis on CDX-2 expression. Thyroid. 2013;23(6):714–9.
Enriquez ML, et al. CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol. 2012;137(5):722–6.
Asioli S, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34(1):44–52.
Asioli S, et al. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol. 2013;44(3):320–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Erickson, L.A. (2014). Papillary Thyroid Carcinoma. In: Atlas of Endocrine Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0443-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0443-3_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0442-6
Online ISBN: 978-1-4939-0443-3
eBook Packages: MedicineMedicine (R0)